XZP-3287 not checked
Xuanzhu Biopharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease”In the company’s words, NCT05077449 on ClinicalTrials.gov
- Tested for
- Advanced Breast Cancer (2 trials)
- Main trialPhase 3
- “This is a phase III clinical trial to evaluate the efficacy and safety of XZP-3287 in combination with Fulvestrant versus placebo combined with Fulvestrant in Patients who have HR positive and Her2 negative recurrent/metastatic breast cancer and have received prior endocrine therapy are eligible for study.”In the company’s words, NCT05077449 on ClinicalTrials.gov
Other drugs for Advanced Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 22 Feb 2024 | A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer | |
| Phase 3Active, not recruiting | 5 Dec 2025 | A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer | |
| Phase 1/2Unknown | 31 Jul 2023 | A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors | |
| Phase 1Unknown | Aug 2021 | Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects | |
| Phase 1Unknown | Sep 2021 | Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects | |
| Phase 1Unknown | 4 Jan 2023 | A Clinical Trial of XZP-3287 for Material Balance |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026